Table 4

Univariate and multivariate analyses of recurrence and survival (Cox regression)
Variables Disease-free survival Overall survival
HR (95% CI) P value HR (95% CI) P value
Univariate analysis
Sex (Male/Female) 1.5 (0.7–3.5) 0.236 1.7 (0.9–3.5) 0.178
Age (≤60/>60) 0.8 (0.4–2.6) 0.421 1.4 (0.9–3.6) 0.279
Histological diagnosis (Head and Body PC/Tail PC) 1.8 (0.9–3.9) 0.145 1.5 (0.6–3.4) 0.243
Clinical stages (I+II/III+IV) 2.8 (1.4–5.9) 0.018 3.2 (0.9–6.7) <0.01
Tumor differentiation (Poor and Moderate/High) 1.2 (0.3–3.7) 0.231 1.8 (0.5–4.4) 0.137
Tumor size (≤4 cm/>4 cm ) 1.8 (0.8–4.1) 0.165 2.2 (1.2–4.2) 0.089
LNM (Negative/Positive) 3.9 (1.1–8.6) <0.01 4.5 (1.5–8.7) <0.01
Liver metastasis (Negative/Positive) 3.5 (1.5–6.4) <0.01 4.1 (1.6–8.5) <0.01
CA199(U/ml) (≤1000/ >1000) 2.4 (0.7–4.3) 0.059 2.0 (0.6–4.8) 0.107
KPS (≤80/>80) 1.9 (0.5–4.8) 0.156 2.3 (0.8–4.7) 0.119
CD44v6 mRNA (Low/High) 3.1 (1.2–6.4) 0.017 2.9 (1.4–6.8) 0.033
Integrin-β1 mRNA (Low/High) 2.7 (1.3–6.3) 0.034 3.2 (1.5–6.8) 0.025
CD44v6 protein (Low/High) 3.2 (1.1–7.1) 0.012 3.9 (1.2–7.5) <0.01
integrin-β1 protein (Low/High) 2.7 (0.8–6.7) 0.045 3.0 (1.1–6.2) 0.013
Multivariate analysis
Clinical stages (I+II/III+IV) 3.5 (0.9–7.5) <0.01 3.6 (1.1–7.1) <0.01
LNM (Negative/Positive) 2.8 (0.6–7.2) 0.033 3.2 (1.0–6.9) 0.021
Liver metastasis(Negative/Positive) 3.3 (0.7–6.8) 0.015 3.5 (1.2–7.5) <0.01
CD44v6 mRNA (Low/High) 2.9 (1.2–6.5) 0.028 2.9 (1.4–6.8) 0.033
Integrin-β1 mRNA (Low/High) 2.4 (0.6–6.7) 0.096 3.2 (1.1–7.2) 0.019
CD44v6 protein (Low/High) 3.3 (1.3–7.8) 0.010 3.7 (1.3–7.5) <0.01
Integrin-β1 protein (Low/High) 2.5 (0.7–6.8) 0.067 3.2 (1.2–6.7) 0.016

Zhou et al.

Zhou et al. Diagnostic Pathology 2013 8:146   doi:10.1186/1746-1596-8-146

Open Data